Soleno Therapeutics

Inactive

SLNO (NasdaqCM)

Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for rare diseases. Its lead candidate, VYKAT XR, is an extended-release tablet for Prader-Willi Syndrome. The company previously operated as Capnia, Inc., changing its name to Soleno Therapeutics in May 2017. It was incorporated in 1999 and is headquartered in Redwood City, California.